| Literature DB >> 23380345 |
Meerim Park1, Soo Hyun Lee, Young Ho Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn, Nak Gyun Chung, Bin Cho, Hack Ki Kim, Kyung Nam Koh, Ho Joon Im, Jong Jin Seo, Dong Kyun Han, Hee Jo Baek, Hoon Kook, Tai Ju Hwang, Eun Kyung Lee, Jeong Ok Hah, Yeon Jung Lim, Hyun Joo Jung, Jun Eun Park, Moon Ju Jang, So Young Chong, Doyeun Oh.
Abstract
Pre-engraftment syndrome (PES) is poorly characterized, and its clinical significance and the prognostic impact after unrelated cord blood transplantation (CBT) are unclear. To address these issues, we retrospectively analyzed the incidence, risk factors, and clinical outcomes of PES in unrelated CBT recipients. Data of 381 patients who received unrelated CBT from 18 medical centers in Korea were reviewed. PES was defined as unexplained fever >38.3°C not associated with infection, and/or unexplained skin rash with or without evidence of fluid retention before neutrophil recovery. PES developed in 102 patients (26.8%) at a median of 7 days after CBT. Of these patients, 74 patients (72.5%) received intravenous corticosteroid at a median dose of 1 mg/kg/day, and of these, 95% showed clinical improvement. Risk factors for developing PES included low risk disease, myeloablative conditioning, graft-versus-host disease (GVHD) prophylaxis without methotrexate or corticosteroid, and >5.43 x 10(7)/kg infused nucleated cells. Absence of PES was one of the risk factors for graft failure in multivariate analysis. The cumulative incidence of grade II to grade IV acute GVHD by 100 days after CBT was higher in patients with PES than in those without PES (56.0% versus 34.4%, P < .01). PES was not associated with chronic GVHD, treatment-related mortality, relapse, or overall survival. PES seems to be common after CBT and may be associated with enhanced engraftment without significant morbidity.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23380345 DOI: 10.1016/j.bbmt.2013.01.014
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742